Biomarker-driven immunotherapy for precision medicine in prostate cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 2. Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin. Adv. Hematol. Oncol. 11(1), 14–23 (2013).
  MedlineGoogle Scholar
• 3. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell. Mol. Immunol. 17(8), 807–821 (2020).
  Medline CASGoogle Scholar
• 4. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 359(6382), 1350–1355 (2018).
  Medline CASGoogle Scholar
• 5. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411–422 (2010).
  Medline CASGoogle Scholar
• 6. Kwon ED, Drake CG, Scher HI et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, Phase 3 trial. Lancet Oncol. 15(7), 700–712 (2014).
  Medline CASGoogle Scholar
• 7. Graff JN, Alumkal JJ, Drake CG et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 7(33), 52810–52817 (2016).
  MedlineGoogle Scholar
• 8. de Almeida DVP, Fong L, Rettig MB, Autio KA. Immune checkpoint blockade for prostate cancer: niche role or next breakthrough? Am. Soc. Clin. Oncol. Educ. Book. 40, 1–18 (2020).
  MedlineGoogle Scholar
• 9. Bilusic M, Madan RA, Gulley JL. Immunotherapy of prostate cancer: facts and hopes. Clin. Cancer Res. 23(22), 6764–6770 (2017).
  Medline CASGoogle Scholar
• 10. Claps M, Mennitto A, Guadalupi V et al. Immune-checkpoint inhibitors and metastatic prostate cancer therapy: learning by making mistakes. Cancer Treat. Rev. 88, 102057 (2020).
  Medline CASGoogle Scholar
• 11. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 19(3), 133–150 (2019).
  Medline CASGoogle Scholar
• 12. Antonarakis ES, Piulats JM, Gross-Goupil M et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, openlabel phase II KEYNOTE-199 study. J. Clin. Oncol. 38, 395–405 (2020). • Antitumor activity of pembrolizumab in a subset of patients with RECIST-measurable and bone-predominant metastatic castration resistant prostate cancer previously treated with docetaxel and targeted endocrine therapy.
  Medline CASGoogle Scholar
• 13. Sharma P, Pachynski RK, Narayan V et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell 38(4), 489–499.e3 (2020).
  Medline CASGoogle Scholar
• 14. Lee L, Ali S, Genega E, Reed D, Sokol E, Mathew P. Aggressive-variant microsatellite-stable POLE mutant prostate cancer with high mutation burden and durable response to immune checkpoint inhibitor therapy. JCO Precis. Oncol. 2, 1–8 (2018).
  MedlineGoogle Scholar
• 15. Guedes LB, Antonarakis ES, Schweizer MT et al. MSH2 loss in primary prostate cancer. Clin. Cancer Res. 23(22), 6863–6874 (2017).
  Medline CASGoogle Scholar
• 16. Antonarakis ES. Cyclin-dependent kinase 12, immunity, and prostate Cancer. N. Engl. J. Med. 379(11), 1087–1089 (2018).
  MedlineGoogle Scholar
• 17. Antonarakis ES, Shaukat F, Isaacsson Velho P et al. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur. Urol. 75(3), 378–382 (2018).
  MedlineGoogle Scholar
• 18. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011). •• Additional hallmarks involved in the pathogenesis of cancers and enabling characteristics that drive tumor progression.
  Medline CASGoogle Scholar
• 19. Knijnenburg TA, Wang L, Zimmermann MT et al. Genomic and molecular landscape of DNA damage repair deficiency across the Cancer Genome Atlas. Cell Rep. 23(1), 239–254 (2018). • Pan-cancer analysis of DNA damage repair deficiency in cancer using integrative genomic and molecular analyses to demonstrate the prognostic utility of DNA damage repair deficiency scores.
  Medline CASGoogle Scholar
• 20. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer 12(1), 68–78 (2011).
  MedlineGoogle Scholar
• 21. Stellato M, Guadalupi V, Sepe P et al. The emerging role of PARP inhibitors in prostate cancer. Expert Rev. Anticancer Ther. 20(8), 715–726 (2020).
  Medline CASGoogle Scholar
• 22. Sishc BJ, Davis AJ. The role of the core non-homologous end joining factors in carcinogenesis and cancer. Cancers (Basel) 9(7), 81 (2017).
  Google Scholar
• 23. Chae YK, Anker JF, Bais P, Namburi S, Giles FJ, Chuang JH. Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. Oncotarget 9(8), 7949–7960 (2017).
  MedlineGoogle Scholar
• 24. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163(4), 1011–1025 (2015).
  MedlineGoogle Scholar
• 25. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4), 707–723 (2017).
  Medline CASGoogle Scholar
• 26. Mateo J, Carreira S, Sandhu S et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373(18), 1697–1708 (2015).
  Medline CASGoogle Scholar
• 27. Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E. BRCA2 and other DDR genes in prostate cancer. Cancers (Basel) 11(3), 352 (2019).
  Medline CASGoogle Scholar
• 28. Lozano R, Castro E, Aragón IM et al. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br. J. Cancer 124(3), 552–563 (2021).
  Medline CASGoogle Scholar
• 29. Jonsson P, Bandlamudi C, Cheng ML et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature 571, 576–579 (2019).
  Medline CASGoogle Scholar
• 30. Pritchard CC, Mateo J, Walsh MF et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375(5), 443–453 (2016). •• Multicenter study assessing the incidence of germline mutations in genes mediating DNA-repair processes among men with metastatic prostate cancer.
  Medline CASGoogle Scholar
• 31. Hempelmann JA, Lockwood CM, Konnick EQ et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. J. Immunother. Cancer 6(1), 29 (2018).
  MedlineGoogle Scholar
• 32. Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J. Immunother. Cancer 6(1), 35 (2018).
  MedlineGoogle Scholar
• 33. Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. The role of neoantigens in response to immune checkpoint blockade. Int. Immunol. 28(8), 411–419 (2016).
  Medline CASGoogle Scholar
• 34. Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371(23), 2189–2199 (2014).
  Medline CASGoogle Scholar
• 35. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124–128 (2015).
  Medline CASGoogle Scholar
• 36. Wu Z, Chen H, Luo W et al. The landscape of immune cells infiltrating in prostate cancer. Front. Oncol. 10, 517637 (2020).
  MedlineGoogle Scholar
• 37. Wang L, Pan S, Zhu B, Yu Z, Wang W. Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer. BMC Urol. 21(1), 29 (2021).
  Medline CASGoogle Scholar
• 38. Subudhi SK, Vence L, Zhao H et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci. Transl. Med. 12(537), eaaz3577 (2020).
  Medline CASGoogle Scholar
• 39. McGrail DJ, Pilié PG, Rashid NU et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32(5), 661–672 (2021).
  Medline CASGoogle Scholar
• 40. Vokes NI, Liu D, Ricciuti B et al. Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non-small-cell lung cancer. JCO Precis. Oncol. 3, PO.19.00171 (2019).
  Google Scholar
• 41. Strickler JH, Hanks BA, Khasraw M. Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin. Cancer Res. 27(5), 1236–1241 (2021).
  Medline CASGoogle Scholar
• 42. Goodman AM, Kato S, Bazhenova L et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16(11), 2598–2608 (2017).
  Medline CASGoogle Scholar
• 43. Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
  Medline CASGoogle Scholar
• 44. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
  Medline CASGoogle Scholar
• 45. Isaacsson Velho P, Antonarakis ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev. Clin. Pharmacol. 11(5), 475–486 (2018).
  MedlineGoogle Scholar
• 46. Haffner MC, Guner G, Taheri D et al. Comprehensive evaluation of programmed death ligand 1 expression in primary and metastatic prostate cancer. Am. J. Pathol. 188, 1478–1485 (2018).
  Medline CASGoogle Scholar
• 47. Hansen AR, Massard C, Ott PA et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann. Oncol. 29, 1807–1813 (2018). • Evidence of durable objective response to pembrolizumab in a subset of patients with heavily pretreated, advanced programmed death-ligand 1-positive prostate cancer.
  Medline CASGoogle Scholar
• 48. Jayaprakash P, Ai M, Liu A et al. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J. Clin. Invest. 128, 5137–5149 (2018).
  MedlineGoogle Scholar
• 49. Fukumura D, Kloepper J, Amoozgar Z et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325–340 (2018).
  Medline CASGoogle Scholar
• 50. Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat. Rev. Clin. Oncol. 12, 584–596 (2015).
  Medline CASGoogle Scholar
• 51. Gooden MJ, de Bock GH, Leffers N et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer 105, 93–103 (2011).
  Medline CASGoogle Scholar
• 52. Fridman WH, Zitvogel L, Sautès-Fridman C et al. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717–734 (2017).
  Medline CASGoogle Scholar
• 53. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17, e542–e551 (2016). •• Exploring tumor-infiltrating lymphocytes, tumor mutation burden, immune gene signatures and multiplex immunohistochemistry to assess predictive biomarker for checkpoint inhibitor-based immunotherapy.
  Medline CASGoogle Scholar
• 54. Miller AM, Lundberg K, Ozenci V et al. CD4⁺CD25^high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol. 177, 7398–7405 (2006).
  Medline CASGoogle Scholar
• 55. Kiniwa Y, Miyahara Y, Wang HY et al. CD8⁺ Foxp3⁺ regulatory T cells mediate immunosuppression in prostate cancer. Clin. Cancer Res. 13, 6947–6958 (2007).
  Medline CASGoogle Scholar
• 56. Zhao SG, Lehrer J, Chang SL et al. The immune landscape of prostate cancer and nomination of PD-l2 as a potential therapeutic target. J. Natl Cancer Inst. 111, 301–310 (2019).
  MedlineGoogle Scholar
• 57. Lundholm M, Hagglof C, Wikberg ML et al. Secreted factors from colorectal and prostate cancer cells skew the immune response in opposite directions. Sci. Rep. 5, 15651 (2015).
  Medline CASGoogle Scholar
• 58. Watanabe M, Kanao K, Suzuki S et al. Abstract 3961: increased CCR4-positive regulatory T cells in biopsy specimen of poor prognosis prostate cancer. Cancer Res. 77, 3961 (2017).
  MedlineGoogle Scholar
• 59. Rayner E, van Gool IC, Palles C et al. A panoply of errors: polymerase proofreading domain mutations in cancer. Nat. Rev. Cancer 16(2), 71–81 (2016).
  Medline CASGoogle Scholar
• 60. Xing X, Kane DP, Bulock CR et al. A recurrent cancer-associated substitution in DNA polymerase ε produces a hyperactive enzyme. Nat. Commun. 10(1), 374 (2019).
  Medline CASGoogle Scholar
• 61. Park VS, Pursell ZF. POLE proofreading defects: contributions to mutagenesis and cancer. DNA Repair (Amst.) 76, 50–59 (2019).
  Medline CASGoogle Scholar
• 62. Wang F, Zhao Q, Wang YN et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol. 5(10), 1504–1506 (2019).
  MedlineGoogle Scholar
• 63. Rousseau BJ, Bieche I, Pasmant E et al. 526O – high activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours. Ann. Oncol. 31(Suppl. 4), S462–S504 (2020).
  Google Scholar
• 64. Blazek D, Kohoutek J, Bartholomeeusen K et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 25(20), 2158–2172 (2011).
  Medline CASGoogle Scholar
• 65. Barrero M, Rediti M, Crespo M et al. Tumor-infiltrating lymphocytes in biallelic-CDK12 mutated prostate cancer. J. Clin. Oncol. 36(Suppl. 15), 5070 (2018).
  Google Scholar
• 66. Wu YM, Cieślik M, Lonigro RJ et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173(7), 1770–1782.e14 (2018).
  Medline CASGoogle Scholar
• 67. Antonarakis ES, Velho PI, Fu W et al. CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors. JCO Precis. Oncol. (4), 370–381 (2020).
  MedlineGoogle Scholar
• 68. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17(9), 559–572 (2017).
  Medline CASGoogle Scholar
• 69. Reimers MA, Yip SM, Zhang L et al. Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer. Eur. Urol. 77(3), 333–341 (2020).
  Medline CASGoogle Scholar
• 70. Hurwitz AA, Foster BA, Kwon ED et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60(9), 2444–2448 (2000).
  Medline CASGoogle Scholar
• 71. Slovin SF, Higano CS, Hamid O et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter Phase I/II study. Ann. Oncol. 24(7), 1813–1821 (2013).
  Medline CASGoogle Scholar
• 72. Beer TM, Kwon ED, Drake CG et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35(1), 40–47 (2017).
  Medline CASGoogle Scholar
• 73. Petrylak DP, Loriot Y, Shaffer DR et al. Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a Phase I study. Clin. Cancer Res. 27(12), 3360–3369 (2021).
  Medline CASGoogle Scholar
• 74. Heery CR, O'Sullivan-Coyne G, Madan RA et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a Phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 18(5), 587–598 (2017).
  Medline CASGoogle Scholar
• 75. Karzai F, Madan RA, Owens et al. A Phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population. J. Clin. Oncol. 36(6), 163 (2018).
  Google Scholar
• 76. Karzai F, VanderWeele D, Madan RA et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J. Immunother. Cancer 6(1), 141 (2018).
  MedlineGoogle Scholar
• 77. Appleman LJ, Kolinsky MP, Berry WR et al. KEYNOTE-365 cohort B: pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—new data after an additional 1 year of follow-up. J. Clin. Oncol. 39(Suppl. 6), 10 (2021).
  Google Scholar
• 78. Fizazi K, González Mella P, Castellano D et al. CheckMate 9KD arm B final analysis: efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer. J. Clin. Oncol. 39(Suppl. 6), 12 (2021).
  Google Scholar
• 79. Sitkovsky MV, Hatfield S, Abbott R et al. Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol. Res. 2, 598–605 (2014).
  Medline CASGoogle Scholar
• 80. Li J, Wang L, Chen X et al. CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non–small cell lung cancer. Oncoimmunology 6, e1320011 (2017).
  MedlineGoogle Scholar
• 81. Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J. Immunother. Cancer 6, 57 (2018).
  MedlineGoogle Scholar
• 82. Bendell J, Bauer T, Patel M et al. Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors. Presented at: AACR Annual Meeting 2019. GA, USA (29 March-3 April 2019).
  Google Scholar
• 83. Porter DL, Levine BL, Kalos M et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
  Medline CASGoogle Scholar
• 84. Porter DL, Hwang W-T, Frey NV et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).
  MedlineGoogle Scholar
• 85. Maude SL, Frey N, Shaw PA et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
  Medline CASGoogle Scholar
• 86. Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 5(9), 915–919 (2015).
  Medline CASGoogle Scholar
• 87. Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat. Rev. Cancer 16(2), 121–126 (2016).
  Medline CASGoogle Scholar
• 88. McGray AJR, Bramson J. Adaptive resistance to cancer immunotherapy. Adv. Exp. Med. Biol. 1036, 213–227 (2017).
  Medline CASGoogle Scholar
• 89. Gubin MM, Zhang X, Schuster H et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515(7528), 577–581 (2014).
  Medline CASGoogle Scholar
• 90. Chowdhury PS, Chamoto K, Honjo T. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J. Intern. Med. 283(2), 110–120 (2018).
  Medline CASGoogle Scholar
• 91. De Bono J, Mateo J, Fizazi K et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382(22), 2091–2102 (2020). •• Results from PROfound trial. Olaparib was associated with longer progression-free survival and better measures of response and patient-reported endpoints than either enzalutamide or abiraterone.
  MedlineGoogle Scholar
• 92. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509–2520 (2015).
  Medline CASGoogle Scholar
• 93. NCCN Guidlines for Prostate Cancer Version 2.2021. http://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459
  Google Scholar
• 94. Parker C, Castro E, Fizazi K et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(9), 1119–1134 (2020).
  Medline CASGoogle Scholar